Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 3 |
Immune System Diseases | 1 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Fusion protein | 2 |
Hormone | 1 |
Genetically engineered subunit vaccine | 1 |
Prophylactic vaccine | 1 |
Top 5 Target | Count |
---|---|
SARS-CoV-2 S protein | 1 |
INSR(Insulin receptor) | 1 |
Target |
Mechanism SARS-CoV-2 S protein modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SARS-CoV-2 S protein inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism INSR agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date10 Feb 2022 |
Sponsor / Collaborator |
Start Date25 Oct 2021 |
Sponsor / Collaborator |
Start Date06 Apr 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
AmbiVax-C ( SARS-CoV-2 S protein ) | COVID-19 More | Phase 3 Clinical |
AKS-107 ( INSR ) | Diabetes Mellitus, Type 1 More | Preclinical |
AKS-130 | Diabetes Mellitus More | Preclinical |
AKS-440 | Diabetes Mellitus More | Preclinical |
AKS-178 | Diabetes Mellitus, Type 2 More | Pending |